Mandrawa Christine L, Stewart Josephine, Fabinyi Gavin C, Walker Susan P
University Department of Obstetrics and Gynaecology, Mercy Hospital for Women, Victoria, Australia.
Aust N Z J Obstet Gynaecol. 2011 Aug;51(4):372-6. doi: 10.1111/j.1479-828X.2011.01314.x. Epub 2011 May 12.
Trastuzumab increases survival amongst women with human epidermal growth factor receptor (HER)-2 receptor positive metastatic breast cancer, but maternal and fetal risks are associated with advanced disease and its treatment in pregnancy. We present a case of a primigravid with HER-2 positive metastatic breast cancer who received trastuzumab throughout pregnancy. She presented with cerebral metastases, requiring surgical decompression and resection. Reversible oligohydramnios developed during pregnancy. Fetal safety data on trastuzumab in pregnancy is limited, but case reports suggest a recurring pattern of (mostly reversible) oligohydramnios.
曲妥珠单抗可提高人表皮生长因子受体（HER）-2受体阳性转移性乳腺癌女性患者的生存率，但晚期疾病及其孕期治疗会带来母婴风险。我们报告一例初产妇，患有HER-2阳性转移性乳腺癌，在整个孕期接受了曲妥珠单抗治疗。她出现了脑转移，需要进行手术减压和切除。孕期出现了可逆性羊水过少。关于曲妥珠单抗在孕期应用的胎儿安全性数据有限，但病例报告提示存在反复出现（大多为可逆性）羊水过少的模式。
